Mangiferin: Bridging Phytochemical Standardization and Therapeutic Translation

Abstract

Mangiferin, a notable bioactive xanthone primarily isolated from Mangifera indica, has attracted considerable interest owing to its diverse pharmacological properties. This review provides a critical evaluation of mangiferin research with a focus on phytochemical standardization, which is imperative for ensuring reproducibility and facilitating clinical translation. A variety of analytical methods, such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, and ultraviolet-visible (UVVis) spectrophotometry, have been employed to accurately characterize and measure mangiferin, emphasizing the importance of thorough analytical approaches. Pharmacologically, mangiferin exhibits antioxidant, antiinflammatory, antidiabetic, anticancer, and neuroprotective properties, highlighting its therapeutic promise in different disease models. Despite promising preclinical results, several challenges in translation remain, including poor bioavailability, formulation issues, and regulatory hurdles, which impede its progress to clinical use. Addressing these challenges through the creation of advanced drug delivery systems, improved standardization methods, and comprehensive regulatory frameworks is crucial to fully harness mangiferin’s clinical potential. Future investigations should prioritize the optimization of analytical standards, improvement of bioavailability, and execution of well-designed clinical trials to substantiate therapeutic efficacy. This integrative strategy will effectively bridge the gap between phytochemical standardization and therapeutic translation, establishing mangiferin as a promising candidate for pharmaceutical development.